ERBB2 is a well-known target gene for treating ERBB2 positive breast cancer. However, few studies assess the effectiveness of ERBB2 targeted therapy in other ERBB2 altered cancers such as ERBB2 mutated non-small cell lung cancer. Therefore, researchers investigated the outcome of ERBB2 targeted therapy in nine NSCLC patients harboring ERBB2 mutations. The response rate was 44% (4/9), and responses lasted about three to ten months. However, in patients without benefit from ERBB2 targeted therapy, a de novo PIK3CA mutation (R245L) as well as ERBB2 copy number gain were identified as potential causes for treatment failure. These findings suggest that testing for ERBB2 mutations may uncover therapeutic options for NSCLC patients who do not harbor other clinically actionable alterations typical for NSCLC.
Publication: J Thorac Oncol. 2017 Feb 4. pii: S1556-0864(17)30090-4.